Business Standard

Friday, December 27, 2024 | 12:49 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Shilpa Medicare slips 12% on USFDA warning letter for Telangana facility

The company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility

The government is now trying to understand how long it will take before the drug’s production can start in India
Premium

SI Reporter Mumbai
Shares of Shilpa Medicare tumbled 12 per cent to Rs 480 on the BSE on Monday after the US health regulator issued a warning letter to the company’s Jadcherla formulations facility in Telangana.

“The company has received a warning letter on 9th October 2020 through email from the United States Food and Drug Administration (USFDA) for its Jadcherla facility, Telangana,” Shilpa Medicare said in exchange filing on Saturday, October 10, 2020.

However, the Company said it believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in